GILD
Gilead Sciences, Inc.
GILD lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
GILD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Strong | |
| Healthy |
GILD's cash flow and balance sheet are currently healthy, and its revenue is stable, but its profitability is weak.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
GILD PE Valuation
GILD has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 20x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
GILD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
GILD has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
GILD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.55 | — |
| Q3 2026 | -$3.15 | -149% |
| Q2 2026 | -$2.66 | -153% |
| Q1 2026 | $7.35 | +54% |
| Q4 2025 | $6.78 | +1684% |
| Q3 2025 | $6.46 | +7078% |
| Q2 2025 | $5.03 | +513% |
| Q1 2025 | $4.76 | +1222% |
| Q4 2024 | $0.38 | -92% |
GILD has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
GILD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.3B | +6.8% |
| Q2 2026 | $7.8B | +10% |
| Q1 2026 | $7B | +4.4% |
| Q4 2025 | $7.9B | +4.7% |
| Q3 2025 | $7.8B | +3% |
| Q2 2025 | $7.1B | +1.8% |
| Q1 2025 | $6.7B | -0.3% |
| Q4 2024 | $7.6B | +6.4% |
GILD's revenue has grown year over year for six quarters in a row: $8.3B last quarter, up 6.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 42% | -1.1 points |
| Q2 2026 | -133% | -168 points |
| Q1 2026 | 37% | +3.6 points |
| Q4 2025 | 25% | -7.4 points |
| Q3 2025 | 43% | +31 points |
| Q2 2025 | 35% | -3.1 points |
| Q1 2025 | 34% | +98 points |
| Q4 2024 | 32% | +9.7 points |
GILD has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over GILD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
GILD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.8B | +21% |
| Q2 2026 | $3.4B | +377% |
| Q1 2026 | $2.4B | +47% |
| Q4 2025 | $3.1B | +10% |
| Q3 2025 | $4B | -5% |
| Q2 2025 | $720M | -40% |
| Q1 2025 | $1.7B | -22% |
| Q4 2024 | $2.8B | +45% |
GILD's free cash flow has been positive every quarter for seven years: $13.8B over the past year, up 50% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over GILD on cash flow, with more consistent year-over-year improvement.
GILD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +8M shares |
| 1 year | -0.2% | -3M shares |
| 3 years | -0.5% | -6M shares |
| 5 years | -0.9% | -11M shares |
| Available history | -2% | -26M shares |
GILD has 1.3B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $370M |
| Q2 2026 | $355M |
| Q1 2026 | $419M |
| Q4 2025 | $230M |
| Q3 2025 | $435M |
| Q2 2025 | $527M |
| Q1 2025 | $730M |
| Q4 2024 | $350M |
GILD spent $1.4B buying back its own shares over the past year, down 33% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over GILD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
GILD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.7x | Healthy |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 2.4x | Moderate |
| Q1 2025 | 2.0x | Healthy |
| Q4 2024 | 8.2x | High |
| Q3 2024 | 10.1x | High |
| Q2 2024 | 5.0x | High |
GILD's net debt is about 1.4 years of its operating earnings (EBITDA), down from 2.0 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over GILD on leverage, with a lower net debt burden relative to earnings.
GILD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.7 | Neutral |
| Stochastic | 83.3 | Overbought |
GILD's weekly RSI is 69 (neutral) and its Stochastic is 83 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
GILD PE vs Healthcare Sector
| Metric | GILD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GILD has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
GILD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $158.1 | 6.3% above |
| 20 week MA | $146.4 | 15% above |
| 50 week MA | $138.9 | 21% above |
| 100 week MA | $124.2 | 35% above |
| 200 week MA | $101.1 | 66% above |
GILD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
GILD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.0 | $57.1 | -13% |
| 2021 | $57.1 | $72.5 | +27% |
| 2022 | $72.5 | $84.8 | +17% |
| 2023 | $84.8 | $81.0 | -4.4% |
| 2024 | $81.0 | $94.1 | +16% |
| 2025 | $94.1 | $124.7 | +33% |
| 2026 YTD | $124.7 | $168.0 | +35% |
GILD has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.